Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

18 June 2002

Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.

Christos Kosmas, Nicolas Tsavaris, Haralambos P Kalofonos

Med Sci Monit 2002; 8(6): PI58-63 :: ID: 420797

Abstract

BACKGROUND: Docetaxel has been the only single agent with proven activityand documented survival benefit in the second-line treatment of advanced/refractory non-small cell lungcancer (NSCLC). Combinations of docetaxel with other active agents in this setting, such as gemcitabine,besides their popularity as front-line treatment, are currently being explored in an attempt to improvethe results over single-agent docetaxel in relapsed/refractory NSCLC.MATERIAL/METHODS: Given the establishedactivity of single-agent docetaxel in two recent large randomized phase III trials against best supportivecare or versus single-agent Vinorelbine or Ifosfamide in patients with platinum pretreated NSCLC, andthe proven activity of single-agent gemcitabine in this setting, combination regimens employing thesetwo agents in various doses and schedules have recently been initiated. Adequately designed phase IIstudies using standard criteria of efficacy and safety, with peer-review based publication, were selectedfrom the literature.RESULTS: The gemcitabine/docetaxel combination in various schedules with or withoutG-CSF support as salvage therapy of NSCLC pre-treated with platinum+paclitaxel-based regimens has beenevaluated in four recently published phase II clinical studies, and has been shown to represent a tolerableand active regimen in this setting, yielding a 10-33% response rate, improvement of disease-related symptoms,and meaningful median and 1-year survival figures in the range of 20-32%. Improvement of disease-relatedsymptoms has outweighed toxicity in all these studies.CONCLUSIONS: Randomized studies are warranted,comparing the gemcitabine/docetaxel combination to single-agent gemcitabine or docetaxel, drugs currentlyrecommended in the second-line treatment of advanced NSCLC.

Keywords: Antineoplastic Combined Chemotherapy Protocols, Clinical Trials, Phase II, Deoxycytidine, paclitaxel, Salvage Therapy, Taxoids

Add Comment 0 Comments

Editorial

01 April 2025 : Editorial  

Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to Humans

Dinah V. Parums

DOI: 10.12659/MSM.949109

Med Sci Monit 2025; 31:e949109

0:00

In Press

Clinical Research  

Serum Prolidase and Ischemia-Modified Albumin Levels in Neural Tube Defects: A Comparative Study of Myelome...

Med Sci Monit In Press; DOI: 10.12659/MSM.947873  

0:00

Clinical Research  

Impact of Depression, Fatigue, and Pain on Quality of Life in Slovak Multiple Sclerosis Patients

Med Sci Monit In Press; DOI: 10.12659/MSM.947630  

Clinical Research  

Longitudinal Evaluation of Metabolic Benefits of Inactivated COVID-19 Vaccination in Diabetic Patients in T...

Med Sci Monit In Press; DOI: 10.12659/MSM.947450  

0:00

Clinical Research  

Impact of Voltage Level on Hospitalization and Mortality in Electrical Injury Cases: A Retrospective Analys...

Med Sci Monit In Press; DOI: 10.12659/MSM.947675  

Most Viewed Current Articles

17 Jan 2024 : Review article   8,000,435

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

16 May 2023 : Clinical Research   702,963

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Mar 2024 : Editorial   30,040

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and ...

DOI :10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

28 Jan 2024 : Review article   23,978

A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future

DOI :10.12659/MSM.943912

Med Sci Monit 2024; 30:e943912

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750